table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
adjuvant therapies
anticoagulant
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...

1 studies excluded by filtering options 0

5895 X-COVID-19, 2021 010selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons